Topics

FDA Grants Orphan Drug Designation to TransThera Biosciences’ TT-00420 for Treatment of Cholangiocarcinoma

11:27 EST 7 Nov 2019 | Speciality Pharma Journal

NANJING, China, Nov. 7, 2019 /PRNewswire/ — TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma. Dr. Frank Wu, Founder and CEO of TransThera, commented: “Cholangiocarcinoma lacks effective therapies and remains a huge …

Original Article: FDA Grants Orphan Drug Designation to TransThera Biosciences’ TT-00420 for Treatment of Cholangiocarcinoma

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to TransThera Biosciences’ TT-00420 for Treatment of Cholangiocarcinoma"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...